Article metrics

Download PDFPDF
Extended report
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

 

Online download statistics by month:

Online download statistics by month: March 2018 to April 2021

AbstractFullPdf
Mar 20182293322118
Apr 2018129715086
May 20181215167104
Jun 201869211562
Jul 20183765134
Aug 20183163321
Sep 20183574621
Oct 20183594329
Nov 20182353728
Dec 20182412514
Jan 20192642113
Feb 20192302711
Mar 20192063815
Apr 20192302313
May 20193183210
Jun 20191912211
Jul 2019204219
Aug 20191363111
Sep 20191563320
Oct 20192473319
Nov 20191283314
Dec 20191721812
Jan 2020143169
Feb 20202163317
Mar 20202162114
Apr 2020197138
May 2020214199
Jun 2020192158
Jul 20201811811
Aug 20201482414
Sep 20201822613
Oct 20202291614
Nov 2020186159
Dec 2020161175
Jan 20211181513
Feb 20212501612
Mar 2021244155
Apr 2021409189
Total131491618845